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Abstract
Background: Although patient attrition is recognized as a threat to the long-term success of antiretroviral therapy programs
worldwide, there is no universal definition for classifying patients as lost to follow-up (LTFU). We analyzed data from health
facilities across Africa, Asia, and Latin America to empirically determine a standard LTFU definition.
Methods and Findings: At a set ‘‘status classification’’ date, patients were categorized as either ‘‘active’’ or ‘‘LTFU’’ according
to different intervals from time of last clinic encounter. For each threshold, we looked forward 365 d to assess the
performance and accuracy of this initial classification. The best-performing definition for LTFU had the lowest proportion of
patients misclassified as active or LTFU. Observational data from 111 health facilities—representing 180,718 patients from
19 countries—were included in this study. In the primary analysis, for which data from all facilities were pooled, an interval
of 180 d (95% confidence interval [CI]: 173–181 d) since last patient encounter resulted in the fewest misclassifications
(7.7%, 95% CI: 7.6%–7.8%). A secondary analysis that gave equal weight to cohorts and to regions generated a similar result
(175 d); however, an alternate approach that used inverse weighting for cohorts based on variance and equal weighting for
regions produced a slightly lower summary measure (150 d). When examined at the facility level, the best-performing
definition varied from 58 to 383 d (mean=150 d), but when a standard definition of 180 d was applied to each facility, only
slight increases in misclassification (mean=1.2%, 95% CI: 1.0%–1.5%) were observed. Using this definition, the proportion of
patients classified as LTFU by facility ranged from 3.1% to 45.1% (mean=19.9%, 95% CI: 19.1%–21.7%).
Conclusions: Based on this evaluation, we recommend the adoption of $180 d since the last clinic visit as a standard LTFU
definition. Such standardization is an important step to understanding the reasons that underlie patient attrition and
establishing more reliable and comparable program evaluation worldwide.
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Unprecedented gains have been made in the expansion of
services for antiretroviral therapy (ART) in resource-constrained
settings. The United Nations Joint Programme for HIV/AIDS
(UNAIDS) now estimates that more than 5 million HIV-infected
adults and children have initiated HIV treatment worldwide, a 13-
fold increase since 2003 [1,2]. Patient attrition and losses to follow-
up, however, have emerged as legitimate threats to the long-term
success of these programs. A systematic review of sub-Saharan
African cohorts reported lost to follow-up (LTFU) rates as high as
35% in the 3 y following ART initiation [3,4], a finding supported
by other regional reports [5–7].
Although commonly described in the context of ART programs,
the accurate categorization of a patient as either active or LTFU
presents unique challenges. An inherent risk to interval-based
definitions for LTFU is misclassification, since a patient who is late
for a clinic appointment may elect to return even after the window
has elapsed. An interval that is close to the visit date, for example,
may be highly sensitive (i.e., a high proportion of patients are
accurately identified as LTFU), but specificity will be low.
Conversely, an interval that is long will be highly specific (i.e., a
high proportion of patients are accurately classified as active), but
sensitivity may be limited.
We developed a methodology to empirically determine the
optimal operational definition for LTFU [8]. Applied to a cohort
of 33,704 ART patients in Lusaka, Zambia [9,10], we found that a
threshold of $56 d since last missed visit led to the fewest
misclassifications of a patient’s status as active or LTFU (5.1%,
95% confidence interval [CI]: 4.8%–5.3%). The primary
limitation of our analysis, however, was its external validity.
Because participating facilities in Lusaka shared many character-
istics (e.g., urban locale, free care, active contact tracing program),
their definition for LTFU might not be appropriate for other
populations. In this report, we apply this methodology to 111
health facilities across three continents and generate an evidence-
based LTFU definition for ART program evaluation worldwide.
Methods
To empirically determine the best-performing definition for
LTFU among adults (i.e., .16 y at ART initiation) on ART, we
analyzed data from six of the seven regions of the International
Epidemiologic Databases to Evaluate AIDS (IeDEA) Collabora-
tion: Central Africa, Eastern Africa, Southern Africa, Western
Africa, Asia/Pacific, and Latin America/Caribbean. Across these
regions, HIV programs from 41 countries contribute unlinked and
anonymous individual-level data to the IeDEA initiative [11]. Use
of these observational data has been approved by ethics
committees and/or institutional review boards in host countries,
as well as through those of international partners. Data for each of
the regions are updated at least annually and managed by RTI
International (Central Africa), Indiana University (Eastern Africa),
University of Bern and University of Cape Town (Southern
Africa), University of Bordeaux (Western Africa), University of
New South Wales (Asia/Pacific), and Vanderbilt University (Latin
America/Caribbean).
Because many programs do not routinely collect information
regarding the date of next clinic visit, a ‘‘days late’’ definition for
LTFU—as used in our Lusaka cohort [8]—may be challenging to
implement globally. For that reason, we sought an optimal LTFU
definition based on the number of days since last clinic encounter.
Our unit of interest was at the level of the health care facility, also
described as ‘‘health centers’’ in this report. To ensure adequate
patient follow-up time, we included only health centers with a
minimum of 200 adults on ART for at least 6 mo at the date of
status classification. Those with patient volumes below this
threshold demonstrated high variability in point estimates.
Facilities with systematic inconsistencies in data collection (e.g.,
only a single documented visit for every patient) were also
excluded.
For each participating facility, we determined the best-
performing definition for LTFU according to the number of
days since last patient encounter. Our methodology has been
described in detail elsewhere [8]. Briefly, at a set ‘‘status
classification’’ date, all patients receiving ART at a given facility
are categorized as either active or LTFU based on thresholds of
1 d to 700 d. In our previous work, we set a single status
classification date (e.g., 31 December 2007) to be used across all
facilities [8]. Because of the larger number of facilities
incorporated into this analysis—and the great variation in their
time of implementation and their dates of data export—status
classification was set either at 12 mo prior to the date of a facility’s
last data export or 12 mo prior to the last date where data entry
appeared complete.
For each threshold interval, we calculated the proportion of
individuals misclassified as either ‘‘false positive’’ (1 – specificity)
or ‘‘false negative’’ (1 – sensitivity) by comparing status at the
classification date and status in the ensuing 12 mo. An individual
who was classified as having been lost who returned to care in
the ensuing 12 mo would constitute a false-positive misclassifi-
cation. On the other hand, an individual who was not classified
as LTFU but never returned by 12 mo would constitute a false-
negative misclassification. The threshold that minimized the
combined false-positive and false-negative misclassification was
considered the best-performing definition for LTFU. If two or
more thresholds resulted in the same misclassification, the one
with shortest duration was designated as the more efficient
definition.
CIs were constructed for the best-performing LTFU thresholds
using a bootstrap approach. Using simple case resampling, 1,000
separate bootstrap samples were generated, and the best-
performing LTFU threshold was determined for each. The
percentile method was used against the resulting distributions to
construct 95% CIs. In our primary analysis, we pooled data from
all facilities to arrive at a standard LTFU definition. We
determined the resulting differences in misclassification when this
overall definition was applied at each facility.
There are currently no ‘‘gold standard’’ methodologies for
calculating a summary LTFU measure from individual facility
data. Recognizing the limitation of our pooled approach, we thus
conducted two secondary analyses. For the first, facilities were
weighted equally to determine a cohort summary measure, cohorts
were weighted equally to determine a regional summary measure,
and regions were weighted equally to arrive at an overall LTFU
definition. Means were used to describe the summary LTFU
definition at each step. In the second approach, we computed a
weighted average of facility-specific LTFU thresholds within each
IeDEA region, using the inverse of the variance of the LTFU
threshold estimate from the corresponding bootstrap distribution.
We then averaged these best-performing regional LTFU defini-
tions to arrive at a summary measure. We sought to determine the
robustness of our primary analysis by comparing its results to the
results of these alternative approaches.
We performed stratified analyses to determine the potential
impact of program characteristics on the best-performing LTFU
definition. Using programmatic data gathered through the IeDEA
Site Assessment Tool (10 June 2009 version)—and verification by
IeDEA regional data managers and facility representatives—we
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setting (i.e., urban or rural), facility type (i.e., private or public),
level of care (i.e., clinic or hospital), presence of a program to
follow up missed visits (including contact tracing, telephone
reminders, and/or letters), provision of free ART, availability of
food supplementation, and provision of family-centered care.
Facilities with partial coverage of these program services—whether
for targeted populations or for only a segment of the observation
period—were categorized as having those characteristics. For
facilities with each characteristic, a pooled approach was used to
determine the best-performing LTFU threshold and its corre-
sponding 95% CI, the latter derived from the bootstrap sampling
described previously. The relationship between optimal LTFU
definition and patient volume was also described using a linear
regression model.
We applied the overall LTFU definition—as described by our
primary analysis—to each participating health center. The overall
proportion of adults classified as LTFU was calculated for each
facility, with 95% CIs determined by the exact binominal method.
All analyses were performed with SAS version 9.13 (SAS
Institute).
Results
Across the six IeDEA regions, observational data were available
from 510 facilities routinely providing ART to adults. Of these
health care centers, 132 had sufficient patient volume to be
included in our analysis (i.e., $200 adults on ART for at least 6
mo at time of status classification). Of these 132 facilities, 21 (16%)
were excluded because of gaps in data collection and/or observed
inconsistencies within the patient-level medical information.
Among the 111 facilities included in our final analysis, five were
located in the Central African region (Democratic Republic of the
Congo), 16 in the Eastern African region (Kenya, Tanzania, and
Uganda), 72 in the Southern Africa region (Botswana, Malawi,
South Africa, Zambia, and Zimbabwe), ten in the Western African
region (Benin, Co ˆte d’Ivoire, Nigeria, and Senegal), six in the
Asia/Pacific region (India, Malaysia, Taiwan, and Thailand), and
two in the Latin America/Caribbean region (Honduras and
Mexico). Data from a total of 180,718 HIV-infected adults on
ART were included. Regional characteristics—including the
number of patients—are shown in Table 1, while individual
facility features are available in Table S1.
Table 1. Characteristics of participating facilities by IeDEA region.
Characteristic
Central African
Region
Eastern
African Region
Southern
African Region
Western
African Region
Asia/Pacific
Region
Latin America/
Caribbean
Region
Number of countries 13 5 44 2
Countries represented Democratic Republic
of the Congo
Kenya, Tanzania,
Uganda
Botswana, Malawi, South
Africa, Zambia, Zimbabwe
Benin, Co ˆte d’Ivoire,
Nigeria, Senegal
India, Malaysia,
Taiwan, Thailand
Honduras, Mexico
Number of facilities 51 6 7 2 1 0 6 2
Patients included in
analysis
3,228 21,945 132,586 20,708 1,651 600
Setting
Urban 5 (100%) 15 (94%) 61 (85%) 10 (100%) 6 (100%) 2 (100%)
Rural 0 (0%) 1 (6%) 11 (15%) 0 (0%) 0 (0%) 0 (0%)
Facility type
Public 0 (0%) 16 (100%) 51 (71%) 8 (80%) 5 (83%) 2 (100%)
Private 5 (100%) 0 (0%) 21 (29%) 2 (20%) 1 (17%) 0 (0%)
Level of care
Clinic 5 (100%) 4 (25%) 45 (63%) 7 (70%) 0 (0%) 0 (0%)
Hospital 0 (0%) 12 (75%) 27 (38%) 3 (30%) 6 (100%) 2 (100%)
Presence of active
follow-up program
Yes 5 (100%) 15 (94%) 51 (71%) 8 (80%) 6 (100%) 1 (50%)
No 0 (0%) 1 (6%) 21 (29%) 2 (20%) 0 (0%) 1 (50%)
Provision of free ART
Yes 5 (100%) 14 (88%) 71 (99%) 9 (90%) 2 (33%) 2 (100%)
No 0 (0%) 2 (12%) 1 (1%) 1 (10%) 4 (67%) 0 (0%)
Food supplementation
available
Yes 2 (40%) 13 (81%) 27 (38%) 5 (50%) 1 (17%) 1 (50%)
No 3 (60%) 3 (19%) 45 (62%) 5 (50%) 5 (83%) 1 (50%)
Family-centered care
provided
Yes 5 (100%) 13 (81%) 2 (3%) 7 (70%) 5 (83%) 2 (100%)
No 0 (0%) 3 (19%) 70 (97%) 3 (30%) 1 (17%) 0 (0%)
doi:10.1371/journal.pmed.1001111.t001
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health centers was 180 d (95% CI: 173–181 d) since last visit
(Figure 1A and 1B). At this threshold, sensitivity was 77.6% (95%
CI: 77.3%–78.0%), specificity was 97.1% (95% CI: 97.0%–
97.2%), positive predictive value was 89.9% (95% CI: 89.6%–
90.2%), and negative predictive value was 93.0% (95% CI:
92.8%–93.1%). Misclassification was at its lowest at this threshold,
at 7.7% (95% CI: 7.6%–7.8%). A secondary analysis that gave
equal weighting to cohorts and to regions produced an optimal
LTFU definition that approximated that of our primary analysis:
using this approach, 175 d was found the best-performing
threshold. When we weighted facilities in each region according
to the inverse of the variance for each optimal LTFU definition,
the best-performing threshold was 150 d.
For each facility, we conducted analyses to empirically
determine the LTFU threshold that resulted in the fewest
misclassifications. Results are shown in Figure 2. The range for
these facility-specific LTFU definitions ranged from 58 d to 383 d
since last visit, with a mean of 150 d (95% CI: 137–163 d). The
lowest misclassification at each facility ranged from 1.2% to
19.0%, with a mean of 7.2% (95% CI: 6.6%–7.8%). When the
summary definition of 180 d—as calculated from our primary
analysis—was applied to each facility, the observed additional
increase in misclassification was between 0% and 5.2%, with a
mean difference of 1.2% (95% CI: 1.0%–1.5%; Figure 3). These
incremental differences in misclassification were slightly higher
when the 175-d definition was applied (mean=1.3%; 95% CI:
1.1%–1.6%) and when the 150-d definition was used (mean=
1.6%; 95% CI: 1.2%–2.1%).
When we stratified according to different facility-level charac-
teristics, only minor differences were observed in the best-
performing definition for setting type or presence of an active
follow-up program. Optimal LTFU definitions differed by $21 d
when patients were categorized according to facility type (35-d
difference), level of care (30-d difference), provision of free ART
(21-d difference), and provision of family-centered care (31-d
difference). The corresponding differences in misclassification,
however, were small and not believed to be practically meaningful
(Table 2). When we examined the relationship between patient
volume and best-performing LTFU definitions, smaller facilities
appeared to have longer optimal thresholds when compared to
health centers with higher enrollments (Figure 4).
Overall, 38,615 of 180,718 (21.4%) patients were classified as
LTFU at the time of status classification based on a definition of
180 d since last visit. At this threshold, the proportion of adults on
ART that would be classified as LTFU ranged from 3.1% to
45.1% (mean=19.9%; 95% CI: 18.1%–21.7%; Figure 5).
Discussion
The objective of this analysis was to empirically determine a
standard LTFU definition that could be used across ART
programs worldwide. To achieve this aim, we used a methodology
that minimized the inaccurate categorization of patients as either
active or LTFU. In a pooled analysis of 111 facilities, a definition
of 180 d for LTFU resulted in the fewest patients misclassified, a
finding generally supported by our other summary approaches.
At present, there is a great deal of variability in LTFU
definitions used across different settings: a standard definition for
LTFU may be valuable in a number of different contexts [12]. In
the area of monitoring and evaluation of ART programs, for
example, managers could use a universal definition to compare
program performance between facilities and/or cohorts. Such an
approach would help to identify ‘‘best practices’’ associated with
low LTFU rates, while providing the necessary framework for
ongoing evaluation and quality improvement. In the area of health
systems research, an empirically determined LTFU definition
could provide much needed standardization to the outcome
measures of clinical trials and epidemiologic studies. In contrast, a
universal definition of LTFU—as proposed in this analysis—might
have a more limited role for patient management. Our best-
performing definition is based on the accurate categorization of
individuals as active or LTFU; it is not designed to identify the
optimal timing for retention activities such as patient recall or
contact tracing.
We encountered methodological challenges in determining our
summary LTFU definition. An analytic approach that pooled all
data would take full advantage of the substantial resources
available through the IeDEA Collaboration; however, larger
facilities, cohorts, and/or regions might be overrepresented in the
final result. An analytical approach that provided more balanced
weighting across the different levels (e.g., cohorts and regions), on
the other hand, would reduce the influence of the largest facilities
at risk of overemphasizing the role of smaller cohorts or regions.
To address this important issue, we conducted three separate
analyses, each taking into account these different strengths and
limitations. Two of these yielded similar results: 180 d as the best
LTFU definition when all data were pooled and 175 d when
cohorts and regions were given equal weighting. The third
approach, which provided weighting inverse to the variance from
each facility’s bootstrap simulations, resulted in an optimal LTFU
Figure 1. Best-performing definition for loss to follow-up.
Demonstrated by receiver-operator curves (A) and misclassification (B)
in the primary pooled analysis.
doi:10.1371/journal.pmed.1001111.g001
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bootstrap modeling and grouped by IeDEA region.
doi:10.1371/journal.pmed.1001111.g002
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region. The shaded portion of each bar represents the misclassification associated with each facility’s best-performing LTFU definition. The white
segment shows the incremental increase in misclassification when the proposed standard definition of 180 d was applied to the health center’s
patient population.
doi:10.1371/journal.pmed.1001111.g003
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visit). Since large health centers exhibited the smallest variances in
our analysis—and since facilities with the largest patient volumes
had the shortest optimal LTFU thresholds (Figure 4)—this finding
was not surprising. Because of the small difference in number of
misclassifications noted between this result and that of our primary
analysis (+0.2%), however, we recommend use of the $180-d
threshold for defining LTFU.
Many ART programs have used a 6-mo absence from the
health care facility to define LTFU [13–15], a practice supported
by our analysis. Because there is no standard definition among
ART programs, other thresholds have also been frequently
considered. In Kenya’s AMPATH (Academic Model Providing
Access to Healthcare) cohort, for example, patients are categorized
as LTFU if more than 3 mo have elapsed since the last clinic
encounter [16,17]. Compared to our proposed 180-d LTFU
definition, such a 90-d threshold would result in only a 2.3%
increase in misclassification (10.0% versus 7.7%) but a 7.3%
(28.7% versus 21.4%) increase among those categorized as LTFU.
If a 365-d definition for LTFU had been used—as done previously
by ART-LINC, ART-CC, and IeDEA investigators [18–20]—
misclassification would increase by 3.3% (11.0% versus 7.7%),
while the proportion categorized as LTFU would decrease by
6.1% (15.3% versus 21.4%). Such differences in reported patient
attrition could have an important impact on program evaluations
and cohort analyses.
Our current analysis represents a substantial extension of a
methodology previously applied to the large, well-characterized
Lusaka ART cohort [8]. We included data from 111 health
centers across three continents, increasing the external validity of
our findings. We calculated the best-performing LTFU definitions
for each of these facilities, demonstrating the differences that may
exist even when health centers share multiple program character-
istics. We also measured LTFU by the days since last visit, a metric
that is more likely to be useful across programs. A LTFU definition
based on ‘‘lateness’’ to the next scheduled clinic visit would
undoubtedly have greater precision, but most electronic medical
records do not routinely provide information on the next
scheduled visit. Where possible, we suggest that the date of next
clinical visit be included in standard program registration and
reporting, particularly given its clear and important role in
coordinating outreach for defaulters.
We recognize that our approach for establishing a universal
definition for LTFU may overlook intricacies inherent to specific
clinics and to specific patients. Appointment schedules, for
example, may change over the course of treatment and may
vary between health care facilities. The capacity to account for
transfers between facilities may also differ, depending on the
availability and sophistication of, and linkages between, electronic
medical records. However, we view this ‘‘real world’’ perspective
as a strength of our approach, particularly given the large
number of clinics included in the analysis. Our final summary
measure may appear imperfect for any one health center, but
performance is markedly improved in the context of multiple
different settings.
When our proposed universal LTFU definition (i.e., 180 d) was
applied to each facility, we observed only small increases in
misclassification, even when the individual health center’s best-
Table 2. Best-performing definition for loss to follow-up when patient populations are stratified according to the different
characteristics of facilities at which they seek care.
Facility Characteristic
Number of
Facilities
Number of
Patients
Best-Performing
Definition, Days
Misclassification
(95% CI)
Setting
Rural 12/111 (11%) 8,635 175 6.9% (6.4%–7.5%)
Urban 99/111 (89%) 172,083 180 7.7% (7.6%–7.9%)
Facility type
Public 81/111 (73%) 154,618 173 7.3% (7.2%–7.5%)
Private 30/111 (27%) 26,100 208 9.6% (9.2%–9.9%)
Level of care
Clinic 57/111 (51%) 84,298 150 6.8% (6.6%–6.9%)
Hospital 54/111 (49%) 96,420 180 8.6% (8.4%–8.8%)
Presence of active follow-up program
Yes 86/111 (77%) 151,931 180 7.5% (7.3%–7.6%)
No 25/111 (23%) 28,787 175 8.9% (8.6%–9.3%)
Provision of free ART
Yes 103/111 (93%) 174,216 180 7.6% (7.4%–7.7%)
No 8/111 (7%) 6,502 159 10.8% (10.1%–11.6%)
Food supplementation available
a
Yes 49/111 (44%) 100,946 180 7.0% (6.9%–7.2%)
No 62/111 (56%) 79,772 173 8.5% (8.3%–8.7%)
Family-centered care provided
Yes 34/111 (32%) 37,294 150 8.9% (8.7%–9.2%)
No 77/111 (68%) 143,424 181 7.3% (7.2%–7.5%)
aAvailable to at least a subset of patients at the facility.
doi:10.1371/journal.pmed.1001111.t002
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explained by the shape of the misclassification curve (Figure 1B).
When facility-specific misclassification curves were reviewed, the
same general trend emerged. As the window for LTFU
classification was extended, there was an initial rapid decline in
misclassification, which dropped to a nadir and then gradually
rose over the subsequent 200 to 300 d. This provided an extended
period across which only small incremental differences are
observed in misclassification.
The more accurate the categorization of active or LTFU is at
the time of status classification, the shorter the optimal LTFU
definition for that specific facility. When many patients returned
to care after extended periods, a longer LTFU threshold was
needed to minimize misclassification [8]. These trends may help
to explain some of the differences observed among facilities.
Characteristics thought to improve patient retention (e.g., free
ART, food supplementation, and active follow-up after missed
visits) were generally associated with optimal LTFU definitions
that were longer (Table 2), suggesting that patients often
returned to care even after a significant period had elapsed
since their last clinic visit. The exception was family-centered
care, where facilities that incorporated such recruitment
strategies had shorter optimal LTFU definitions (150 d, versus
181 d for facilities that did not have family-centered care).
Interestingly, patient volume was inversely associated with the
length of the health facility’s best-performing LTFU threshold.
Specifically, health care centers with larger patient volumes
appeared to have shorter optimal LTFU definitions. The
increased waiting times typically associated with such crowded
and overburdened settings likely serve as an important obstacle
for retention; as a result, those on ART more quickly distinguish
themselves as either active or LTFU.
We note several limitations to this analysis. First, while we
advocate for establishment of a universal LTFU threshold, we
recognize the marked heterogeneity in best-performing definitions
among participating facilities (Figure 2). While we were reassured
by the marginal differences in misclassification when the 180-d
threshold was applied, it is possible that—in certain contexts—
local, national, or regional definitions may be more appropriate
for program evaluation. In these situations, the methodology
described in this report can be used to determine specific LTFU
thresholds for the populations of interest. Second, we did not
include HIV-infected patients who sought care but were not yet
eligible for treatment, a population that has been shown to have
high rates of attrition [21,22]. Optimal LTFU definitions for the
‘‘pre-ART’’ population are likely longer than for those initiating
ART and should be explored further. Third, we observed
instability in our point estimates when this methodology was
Figure 4. Association between patient volume and optimal definition for loss to follow-up across 111 participating facilities. The line
represents the results of a linear regression model, while the shaded portion represents its 95% CI.
doi:10.1371/journal.pmed.1001111.g004
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doi:10.1371/journal.pmed.1001111.g005
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collection. As a result, we were unable to use data from many
smaller facilities contributing data to the IeDEA Collaboration.
That we were able to include the vast majority (84%) of health
facilities meeting our eligibility criteria does, however, provide
some confidence as to the external validity of our findings. Fourth,
African facilities were heavily represented since these are the
regions where program expansion has been most rapid. When the
final summary definition was applied to the Asian and Latin
American facilities in our study, there was a relatively low
difference in misclassification (#5%), suggesting that our findings
are robust and applicable to programs outside of sub-Saharan
Africa. Fifth, standardization of LTFU definitions represents only
the first step in improving patient retention. Further research
is needed to understand individual- and facility-level predictors
of LTFU, so that at-risk populations can be identified and
appropriate interventions can be evaluated [12].
A universal LTFU definition for ART program monitoring
is clearly needed, but how would such standardization be
best achieved? Because of the wide range of LTFU thres-
holds already in use [3], we advocate a top-down approach.
Consensus for key monitoring and evaluation parameters
(including LTFU) should first be established, based on input
from program managers, policymakers, and program funders.
In these deliberations, a broad range of criteria must be applied.
Although we focus on the proper classification of patient status
in this analysis—and believe it to be critical—other factors (e.g.,
clinical care implications and infrastructural demands) deserve
consideration as well. Once established, buy-in from local
governments and funders will be needed so that these consensus
definitions are incorporated into routine program reporting. In
some settings, implementation will require only minor adjust-
ments to existing registers, electronic medical records, and data
reporting systems (e.g., national-level health management
information systems). The United States President’s Emergency
P l a nf o rA I D SR e l i e f ,f o re x a m p l e ,a l r e a d yh a ss t a n d a r d
reporting requirements [23] and similar measures have been
adopted by local governments as well [24]. In other contexts,
investment may be needed, both in terms of equipment and
human resources, to ensure that such information is captured in
a proper and timely fashion. Finally, such standardization will
be useful only if data are routinely collected and reviewed.
Ongoing monitoring is needed to ensure that feedback loops
back to facilities are intact.
In conclusion, based on this large evaluation of 111 health
facilities, we recommend a threshold of 180 d since the last cli-
nic visit as a standard definition for LTFU. Harmonization of
monitoring and evaluation activities in this manner is an
important step towards understanding the phenomenon of
patient attrition within and between cohorts worldwide. Stan-
dardization is also crucial to the development and comprehensive
implementation of methodology correcting for bias in measures of
program effectiveness, including assessment of mortality [25–27]
and estimation of major disease markers such as CD4 counts.
Finally, it provides the necessary framework for continued re-
search to improve patient retention [28–30], so that the health
gains from HIV treatment programs may be maximized and
sustained.
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Background. Since 1981, AIDS has killed more than 25
million people, and about 33 million people (mostly in low-
and middle-income countries) are now infected with HIV, the
virus that causes AIDS. Because HIV destroys immune system
cells, HIV-positive individuals are very susceptible to other
infections, and, early in the AIDS epidemic, most HIV-infected
people died within ten years of contracting the virus. Then,
in 1996, antiretroviral therapy (ART)—a cocktail of drugs that
keeps HIV in check—became available. For people living in
developed countries, HIV infection became a chronic condi-
tion. However, for people living in developing countries, ART
was prohibitively expensive, and HIV/AIDS remained a fatal
illness. In 2003, this situation was declared a global emer-
gency, and governments, international agencies, and
funding bodies began to implement plans to increase ART
coverage in resource-limited countries. By the end of 2009,
more than a third of people living in these countries who
needed ART were receiving it.
Why Was This Study Done? Because ART does not cure
HIV infection, patients have to take antiretroviral drugs
regularly for the rest of their lives. But in some ART programs,
more than a third of patients are lost to follow-up (LTFU),
that is, they stop coming for treatment, within three years of
starting treatment. Patient attrition threatens the success of
ART programs, but to understand why it occurs, a stan-
dardized method for classifying patients as LTFU is essential.
Classification of patients as LTFU relies on an interval-based
definition of LTFU. That is, a patient who fails to attend a
clinic within a specified interval after a previous visit is
classified as LTFU. If this interval is too short, although many
patients will be accurately identified as LTFU, there will be a
high false-positive rate—some patients classified as LTFU will
actually return to the clinic later. Conversely, if the interval is
too long, some patients who are truly LTFU will be mis-
classified as active (a false-negative classification). In this
study, the researchers analyzed data from health facilities
across Africa, Asia, and Latin America to determine a standard
definition for LTFU that minimizes patient misclassification.
What Did the Researchers Do and Find? Using data
collected from 111 health facilities by the International
Epidemiologic Databases to Evaluate AIDS (IeDEA) Collabora-
tion, the researchers categorized patients receiving ART at
each facility at a ‘‘status classification’’ date (12 months
before the facility’s last data export to IeDEA) as active or
LTFU using a range of intervals (thresholds) since their last
clinic visit. For example, for a test interval of 200 days,
patients who had not revisited the clinic within 200 days of
their previous visit at the status classification date were
classified as LTFU; patients who had revisited the clinic were
classified as active. The researchers then looked forward 365
days from the status classification date to assess the
performance and accuracy of these classifications. So, a
‘‘LTFU’’ patient who visited the clinic anytime during the year
after the status classification date represented a false-
positive classification, and an ‘‘active’’ patient who did not
return within the ensuing year represented a false-negative
classification. When data from all the facilities were pooled, a
threshold of 180 days produced the fewest misclassifications.
At the facility level, the best-performing threshold for patient
classification ranged from 58 to 383 days (with an average of
150 days), but application of a 180-day threshold to indivi-
dual facilities only slightly increased misclassifications. Finally,
using the 180-day threshold, average LTFU at individual
facilities was 19.9%.
What Do These Findings Mean? Based on these findings,
the researchers recommend that the standard definition for
LTFU should be when it has been 180 days or more since the
patient’s last clinic visit. Given the wide range of best-
performing definitions among facilities, however, they recog-
nize that local, national, or regional definitions of LTFU may
be more appropriate in certain contexts. Adoption of a
standard definition for LTFU, the researchers note, should
facilitate harmonization of monitoring and evaluation of ART
programs across the world and should help to identify ‘‘best
practices’’ associated with low LTFU rates. Importantly, it
should also provide the necessary framework for research
designed to improve patient retention in ART programs,
thereby helping to maximize and sustain the health gains
from HIV treatment programs.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001111.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV/AIDS treatment and care and on universal
access to AIDS treatment (in English and Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment (in several languages)
N Information about the IeDEA Collaboration is available
N Patient stories about living with HIV/AIDS are avai-
lable through Avert and through the charity website
Healthtalkonline
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